Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of S-898270 in Healthy Japanese and White Adults and Healthy Japanese Elderly
jRCT2031250224Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing S-898270 with Placebo (2 arms). Primary endpoints: Safety and tolerability assessed by adverse events, Safety assessed by clinical laboratory tests and 4 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
S-898270
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250224.